Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 2Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

venetoclax 2daratumumab 2Dexamethasone 2Bortezomib 2prednylidene 1pegaspargase 1nelarabine 1merphos 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1capivasertib 1calaspargase pegol 1auricularum 1Vincristine 1Thioguanine 1Spinal Puncture 1Specimen Handling 1Radiotherapy 1Radiation 1Prednisone 1Prednisolone 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Medrol Veriderm 1Magnetic Resonance Spectroscopy 1Hydrocortisone 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Medrol Veriderm × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡